Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Fred Puppet who wrote (1836)	3/16/1999 10:19:00 PM
From: Jon Koplik	Respond to of 2135

I think you are doing a little of what you accused others of doing -- assuming something that none of us really have a clue about ... ENMD won't move on to a small molecule because they're the type to go broke in pursuit of good science, and to hell with profits. What if ENMD has been aware of this small molecule stuff for a long time, and has already been working on it ? It is entirely feasible, since it is within their area of expertise. Jon.

To: Fred Puppet who wrote (1836)	3/16/1999 10:26:00 PM
From: David Winkler	Respond to of 2135

The most likely small molecule would be the active fragment of Angiostatin. Enmd would own that. Other small molecules, if they could get through the cell membrane would inhibit intracellular ATP synthase resulting in a shut down of metabolic activity in the cell. I like the idea of an antibody against the enzyme, but there are problems with that too. I am willing to bet there are some peptide synthesizers running tonight, making peptides for generating antibodies to ATP sythase. There is so much confusion that it is impossible for anyone to have a full grasp of what is going on. Some of the confusion is expected, some a result of ignorance, but there are some on both sides who are putting out deliberate misinformation. Statements like the one from Duke "I don't expect it to be a viable product..." are no better than Watson's euphoric statement last May. What material was Duke using? I don't have a clue, but I will bet it is not what entremed is making now.